Log in

X4 Pharmaceuticals Stock Forecast, Price & News

+0.19 (+2.82 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $6.92
50-Day Range
MA: $6.39
52-Week Range
Now: $6.92
Volume43,537 shs
Average Volume83,047 shs
Market Capitalization$112.71 million
P/E RatioN/A
Dividend YieldN/A
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.84 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:XFOR



Sales & Book Value

Annual SalesN/A
Book Value$10.37 per share


Net Income$-52,810,000.00


Market Cap$112.71 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
+0.19 (+2.82 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XFOR News and Ratings via Email

Sign-up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

X4 Pharmaceuticals (NASDAQ:XFOR) Frequently Asked Questions

How has X4 Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

X4 Pharmaceuticals' stock was trading at $8.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XFOR stock has decreased by 19.3% and is now trading at $6.92.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of X4 Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for X4 Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than X4 Pharmaceuticals?

Wall Street analysts have given X4 Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but X4 Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is X4 Pharmaceuticals' next earnings date?

X4 Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for X4 Pharmaceuticals

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced its quarterly earnings results on Thursday, November, 5th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.13.
View X4 Pharmaceuticals' earnings history

What price target have analysts set for XFOR?

7 Wall Street analysts have issued 12 month price targets for X4 Pharmaceuticals' shares. Their forecasts range from $15.00 to $21.00. On average, they expect X4 Pharmaceuticals' share price to reach $18.50 in the next twelve months. This suggests a possible upside of 167.3% from the stock's current price.
View analysts' price targets for X4 Pharmaceuticals

Who are some of X4 Pharmaceuticals' key competitors?

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

Who are X4 Pharmaceuticals' key executives?

X4 Pharmaceuticals' management team includes the following people:
  • Dr. Paula Ragan, Founder, CEO, Pres, Sec. & Director (Age 50, Pay $779.45k)
  • Mr. Adam S. Mostafa, CFO, Treasurer & Assistant Sec. (Age 40, Pay $541.64k)
  • Dr. Mary DiBiase, Sr. VP of Technical Operations & Quality
  • Ms. Candice Ellis, Director of Corp. Communications & Investor Relations
  • Mr. Derek M. Meisner Esq., J.D., Gen. Counsel (Age 49)
  • Ms. Ronny Mosston, Sr. VP of HR
  • Dr. Robert David Arbeit, Sr. VP of Clinical Devel. and Translational Research (Age 72)
  • Dr. Nic G. Scalfarotto, Sr. VP of Regulatory Affairs
  • Ms. Carrie Melvin M.B.A., Sr. VP of Devel. Operations

What is X4 Pharmaceuticals' stock symbol?

X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."

Who are X4 Pharmaceuticals' major shareholders?

X4 Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.06%), AXA S.A. (3.35%), State Street Corp (2.60%), Boothbay Fund Management LLC (0.47%), ClariVest Asset Management LLC (0.28%) and Morgan Stanley (0.10%). Company insiders that own X4 Pharmaceuticals stock include Adam S Mostafa, Derek M Meisner, Paula Ragan and Renato Skerlj.
View institutional ownership trends for X4 Pharmaceuticals

Which institutional investors are selling X4 Pharmaceuticals stock?

XFOR stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, JPMorgan Chase & Co., New York State Common Retirement Fund, and Morgan Stanley. Company insiders that have sold X4 Pharmaceuticals company stock in the last year include Adam S Mostafa, Derek M Meisner, Paula Ragan, and Renato Skerlj.
View insider buying and selling activity for X4 Pharmaceuticals

Which institutional investors are buying X4 Pharmaceuticals stock?

XFOR stock was purchased by a variety of institutional investors in the last quarter, including Boothbay Fund Management LLC, AXA S.A., BlackRock Inc., ClariVest Asset Management LLC, and State Street Corp.
View insider buying and selling activity for X4 Pharmaceuticals

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is X4 Pharmaceuticals' stock price today?

One share of XFOR stock can currently be purchased for approximately $6.92.

How big of a company is X4 Pharmaceuticals?

X4 Pharmaceuticals has a market capitalization of $112.71 million. The company earns $-52,810,000.00 in net income (profit) each year or ($4.63) on an earnings per share basis. X4 Pharmaceuticals employs 64 workers across the globe.

What is X4 Pharmaceuticals' official website?

The official website for X4 Pharmaceuticals is www.x4pharma.com.

How can I contact X4 Pharmaceuticals?

X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-529-8300 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.